CervoMed said its investigational medicine neflamapimod has received an Innovation Passport designation in the UK under the Innovative Licensing and Access Pathway, or ILAP, for the treatment of dementia with Lewy bodies (DLB). The designation is aimed at helping promising therapies move through development and review more efficiently.
According to the announcement, the Innovation Passport is designed to support a faster path to market and to improve the timeline for patient access when a medicine may offer meaningful clinical benefit. For CervoMed, the recognition puts neflamapimod into a UK framework intended to assist potentially transformative new treatments.
The development is notable for dementia with Lewy bodies, a condition with significant unmet medical need and limited treatment options. By being selected for the ILAP process, neflamapimod could benefit from a more coordinated regulatory and access pathway in the UK as the program advances.
While the company did not frame the designation as an approval, the award marks an important regulatory milestone for neflamapimod in DLB. It also highlights continued interest in speeding access to investigational medicines that could make a difference for patients with neurodegenerative disease.
